Fate Therapeutics Receives $15 Million CIRM Grant for Clinical Trials
What happened
Fate Therapeutics announced it received a $15.0 million grant from the California Institute for Regenerative Medicine (CIRM). The funding is designated for the clinical development of RECLAIM-LN, the company's Phase 2 trial of FT819 off-the-shelf CAR T-cell therapy. This therapy is being evaluated for patients with refractory moderate-to-severe Systemic Lupus Erythematosus (SLE) with Lupus Nephritis (LN).
From manilatimes.net
Why it matters
The CIRM grant supports the company's efforts to advance its pipeline of induced pluripotent stem cell-derived cellular immunotherapies. This funding is intended to support the clinical evaluation of the therapy, which aims to transform clinical practice for patients with severe lupus.
Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
From manilatimes.net
Who's involved
- Fate TherapeuticsClinical-stage biopharmaceutical company developing stem cell therapies
- FDARegulatory body relied upon for evaluation and accelerated market pathways
- NasdaqAmerican stock exchange where Fate Therapeutics is publicly listed
- Jefferies Financial GroupFinancial services company providing market coverage for Fate Therapeutics
- San DiegoLocation where Fate Therapeutics conducts its operations
Keep exploring
The entities involved
-
Fate Therapeutics
a clinical-stage biopharmaceutical company in San Diego, United States
Nothing else this week.